Kawauchi Akihiro, Yoneda Kimihiko, Fujito Akira, Okihara Koji, Soh Jintetsu, Naitoh Yasuyuki, Mizutani Yoichi, Miki Tsuneharu
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Urology. 2007 Jan;69(1):53-6. doi: 10.1016/j.urology.2006.09.009.
To evaluate and compare the oncologic outcome of hand-assisted retroperitoneoscopic radical nephrectomy (HALS) with that of open radical nephrectomy.
The clinical and follow-up data of 123 patients with localized renal cell carcinoma who underwent HALS were retrospectively compared with those of 70 patients who underwent open radical nephrectomy.
No significant differences were found in operating time, complication rates, or transfusion rates between the HALS and open groups. The estimated blood loss was significantly less in the HALS group. The median follow-up period was 41.0 months for the HALS group, significantly shorter than that for the open group (74.5 months). The 3 and 5-year disease-free survival rate for the HALS and open groups was 94% and 92% and 93% and 91%, respectively. The 3 and 5-year cancer-specific survival rate for the HALS and open groups was 96% and 92% and 98% and 94%, respectively. No significant differences were found in the disease-free and cancer-specific survival rates between the two groups. In the HALS group, no significant differences were found in the disease-free survival rate between those undergoing surgery by less-experienced surgeons who had performed laparoscopic nephrectomy on 10 cases or less and those undergoing surgery by more experienced surgeons.
The oncologic outcome of HALS did not differ much from that of the open approach. Also, the experience of the surgeon did not affect the oncologic outcome. However, extended follow-up is necessary to assess the true oncologic efficacy of HALS.
评估并比较手辅助后腹腔镜根治性肾切除术(HALS)与开放性根治性肾切除术的肿瘤学结局。
回顾性比较123例行HALS的局限性肾细胞癌患者与70例行开放性根治性肾切除术患者的临床及随访数据。
HALS组与开放手术组在手术时间、并发症发生率或输血率方面未发现显著差异。HALS组的估计失血量显著更少。HALS组的中位随访期为41.0个月,显著短于开放手术组(74.5个月)。HALS组和开放手术组的3年和5年无病生存率分别为94%和92%、93%和91%。HALS组和开放手术组的3年和5年癌症特异性生存率分别为96%和92%、98%和94%。两组在无病生存率和癌症特异性生存率方面未发现显著差异。在HALS组中,实施腹腔镜肾切除术10例及以下的经验较少的外科医生与经验更丰富的外科医生手术患者的无病生存率未发现显著差异。
HALS的肿瘤学结局与开放手术方法相比差异不大。此外,外科医生的经验并未影响肿瘤学结局。然而,需要延长随访时间以评估HALS真正的肿瘤学疗效。